An 18-year Follow-up Study on OSA in a Population-based Cohort

Launched by CHINESE UNIVERSITY OF HONG KONG · Oct 2, 2021

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how obstructive sleep apnea (OSA) affects people over time, particularly looking at its impact on heart health and brain function. The study is inviting participants from a group of children who were originally studied in 2003 to join an 18-year follow-up. Researchers will collect information through questionnaires, sleep studies, blood pressure monitoring, heart scans, and brain function tests.

To be eligible, participants must have been part of the original 2003 study. However, some individuals may not be able to participate if they have certain medical conditions, like severe lung diseases or specific neurological issues. For those who join, they can expect to complete various assessments to help researchers learn more about how OSA can affect health over many years. It’s important to note that if a participant is unwell or taking specific medications close to the study date, their appointment may be rescheduled to ensure accurate results.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - Subjects participants from the 2003 cohort
• Exclusion Criteria:
• • Neuromuscular disease
• • Pathological central apnoea
• • Severe chronic lung disease with documented hypoxaemia or awake oxygen saturation \<92%
• • Chronic respiratory failure (unrelated to OSA)
• • Acquired upper airway disease/obstruction
• • Craniofacial abnormalities (e.g. secondary to trauma and malignancy)
• Other arrangement:
• • Subjects who have any respiratory illness within 2 weeks of the scheduled follow-up visit will have their assessment re-arranged until they have fully recovered.
• • Subjects taking medications that may affect sleep, upper airway patency or blood pressure (for example sedatives, stimulants, antihistamines, and cough medicine) within a week from recruitment will also be rescheduled to participate when they are free from medication use for at least 2 weeks.
• • Subjects with hypertension and are on anti-hypertensive therapy are allowed to continue on their medication and the information will be obtained and recorded during data collection.